Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer (original) (raw)

• Blander, G. & Guarente, L. The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 73, 417–435 (2004).
  CAS PubMed Google Scholar
• Gregoretti, I. V., Lee, Y. M. & Goodson, H. V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338, 17–31 (2004). An insightful phylogenetic analysis of HDACs.
  CAS PubMed Google Scholar
• Leipe, D. D. & Landsman, D. Histone deacetylases, acetoin utilization proteins and acetylpolyamine amidohydrolases are members of an ancient protein superfamily. Nucleic Acids Res. 25, 3693–3997 (1997).
  CAS PubMed PubMed Central Google Scholar
• Kouzarides, T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 19, 1176–1179 (2000).
  CAS PubMed PubMed Central Google Scholar
• Richmond, T. J. & Davey, C. A. The structure of DNA in the nucleosome core. Nature 423, 145–150 (2003).
  CAS PubMed Google Scholar
• Strahl, B. D. & Allis, C. D. The language of covalent histone modifications. Nature 403, 41–45 (2000).
  CAS Google Scholar
• Turner, B. M. Cellular memory and the histone code. Cell 111, 285–291 (2002). References 6 and 7 contain the proposal and one of the counter-proposals of the histone code.
  CAS PubMed Google Scholar
• Turner, B. M. Reading signals on the nucleosome with a new nomenclature for modified histones. Nature Struct. Mol. Biol. 12, 110–112 (2005).
  CAS Google Scholar
• Allfrey, V. G., Faulkner, R. & Mirsky, A. E. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl Acad. Sci. USA 51, 786–794 (1964).
  CAS PubMed Google Scholar
• Polo, S. E. & Almouzni, G. Histone metabolic pathways and chromatin assembly factors as proliferation markers. Cancer Lett. 220, 1–9 (2005).
  CAS PubMed Google Scholar
• Vidanes, G. M., Bonilla, C. Y. & Toczyski, D. P. Complicated tails: histone modifications and the DNA damage response. Cell 121, 973–976 (2005).
  CAS PubMed Google Scholar
• Weinreich, M., Palacios DeBeer, M. A. & Fox, C. A. The activities of eukaryotic replication origins in chromatin. Biochim. Biophys. Acta 1677, 142–157 (2004).
  CAS PubMed Google Scholar
• Zhang, J., Xu, F., Hashimshony, T., Keshet, I. & Cedar, H. Establishment of transcriptional competence in early and late S phase. Nature 420, 198–202 (2002).
  CAS PubMed Google Scholar
• Mann, M. & Jensen, O. N. Proteomic analysis of post-translational modifications. Nature Biotechnol. 21, 255–261 (2003).
  CAS Google Scholar
• Qiang, L., Xiao, H., Campos, E. I., Ho, V. C. & Li, G. Development of a PAN-specific, affinity-purified anti-acetylated lysine antibody for detection, identification, isolation, and intracellular localization of acetylated protein. J. Immunoassay Immunochem. 26, 13–23 (2005).
  CAS PubMed Google Scholar
• Ronzoni, S., Faretta, M., Ballarini, M., Pelicci, P. & Minucci, S. New method to detect histone acetylation levels by flow cytometry. Cytometry A 66, 52–61 (2005).
  PubMed Google Scholar
• Caron, C., Boyault, C. & Khochbin, S. Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability. Bioessays 27, 408–415 (2005).
  CAS PubMed Google Scholar
• Giandomenico, V., Simonsson, M., Grönroos, E. & Ericsson, J. Coactivator-dependent acetylation stabilizes members of the SREBP family of transcription factors. Mol. Cell. Biol. 23, 2587–2599 (2003).
  CAS PubMed PubMed Central Google Scholar
• Grönroos, E., Hellman, U., Heldin, C. H. & Ericsson, J. Control of Smad7 stability by competition between acetylation and ubiquitination. Mol. Cell 10, 483–493 (2002).
  PubMed Google Scholar
• Jin, Y. H. et al. Transforming growth factor-β stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J. Biol. Chem. 279, 29409–29417 (2004).
  CAS PubMed Google Scholar
• Rausa, F. M., Hughes, D. E. & Costa, R. H. Stability of the hepatocyte nuclear factor 6 transcription factor requires acetylation by the CREB-binding protein coactivator. J. Biol. Chem. 279, 43070–43076 (2004).
  CAS PubMed Google Scholar
• Munshi, N et al. Coordination of a transcriptional switch by HMGI(Y) acetylation. Science 293, 1133–1136 (2001).
  CAS PubMed Google Scholar
• Yuan, Z. L., Guan, Y. J., Chatterjee, D. & Chin, Y. E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307, 269–273 (2005).
  CAS PubMed Google Scholar
• Wang, R., Cherukuri, P. & Luo, J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J. Biol. Chem. 280, 11528–11534 (2005).
  CAS PubMed Google Scholar
• Jeong, J. W. et al. Regulation and destabilization of HIF-1α by ARD1-mediated acetylation. Cell 111, 709–7020 (2002).
  CAS PubMed Google Scholar
• Bilton, R. et al. Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1α and is not induced by hypoxia or HIF. J. Biol. Chem. 280, 31132–31140 (2005).
  CAS PubMed Google Scholar
• Cohen HY, et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol. Cell 13, 627–638 (2004). Cytoplasmic role for acetylation of Ku70 in apoptosis.
  CAS PubMed Google Scholar
• Cohen, H. Y. et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305, 390–392 (2004).
  CAS PubMed Google Scholar
• Bonaldi, T. et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22, 5551–5560 (2003).
  CAS PubMed PubMed Central Google Scholar
• Bannister, A. J., Miska, E. A., Görlich, D. & Kouzarides, T. Acetylation of importin-α nuclear import factors by CBP/p300. Curr. Biol. 10, 467–470 (2000).
  CAS PubMed Google Scholar
• Caillaud, A. et al. Acetylation of interferon regulatory factor-7 by p300/CREB-binding protein (CBP)-associated factor (PCAF) impairs its DNA binding. J. Biol. Chem. 277, 49417–49421 (2002).
  CAS PubMed Google Scholar
• Choi, C. H., Hiromura, M. & Usheva, A. Transcription factor IIB acetylates itself to regulate transcription. Nature 424, 965–969 (2003).
  CAS PubMed Google Scholar
• Hasan, S. et al. Acetylation regulates the DNA end-trimming activity of DNA polymerase β. Mol. Cell 10, 1213–1222 (2002).
  CAS PubMed Google Scholar
• Hasan, S. et al. Regulation of human flap endonuclease-1 activity by acetylation through the transcriptional coactivator p300. Mol. Cell 7, 1221–1231 (2001).
  CAS PubMed Google Scholar
• Bode, A. M. & Dong, Z. Post-translational modification of p53 in tumorigenesis. Nature Rev. Cancer 4, 793–805 (2004).
  CAS Google Scholar
• Chen, L. F. & Greene, W. C. Shaping the nuclear action of NF-κB. Nature Rev. Mol. Cell Biol. 5, 392–401 (2004).
  CAS Google Scholar
• Kawaguchi, Y. et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115, 727–738 (2003).
  CAS PubMed Google Scholar
• Kovacs, J. J. et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18, 601–607 (2005). Role of acetylation in the control of the chaperone function of HSP90.
  CAS PubMed Google Scholar
• Lagger, G. et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 21, 2672–2681 (2002). Genetic demonstration that HDAC1 is essential for proliferation in mammals.
  CAS PubMed PubMed Central Google Scholar
• Zhang, C. L. et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110, 479–488 (2002).
  CAS PubMed PubMed Central Google Scholar
• Vega, R. B. et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119, 555–566 (2004).
  CAS PubMed Google Scholar
• Minucci, S., Nervi, C., Lo Coco, F. & Pelicci, P. G. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20, 3110–3115 (2001).
  CAS PubMed Google Scholar
• Warrell, R. P. et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med. 324, 1385–1393 (1991).
  PubMed Google Scholar
• Minucci, S. & Pelicci, P. G. Retinoid receptors in health and disease: co-regulators and the chromatin connection. Semin. Cell Dev. Biol. 10, 215–225 (1999).
  CAS PubMed Google Scholar
• Lin, R. J., Egan, D. A. & Evans, R. M. Molecular genetics of acute promyelocytic leukemia. Trends Genet. 15, 179–184 (1999).
  CAS PubMed Google Scholar
• Lin, R. J. & Evans, R. M. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol. Cell 5, 821–830 (2000).
  CAS PubMed Google Scholar
• Minucci, S. et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol. Cell 5, 811–820 (2000).
  CAS PubMed Google Scholar
• Di Croce, L. et al. Altered epigenetic signals in human disease. Cancer Biol. Ther. 3, 831–837 (2004).
  CAS PubMed Google Scholar
• Di Croce, L. et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295, 1079–1082 (2002).
  CAS PubMed Google Scholar
• He, L. Z. et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 108, 1321–1330 (2001).
  CAS PubMed PubMed Central Google Scholar
• Brown, D. et al. A _PMLRAR_α transgene initiates murine acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA 94, 2551–2556 (1997).
  CAS PubMed Google Scholar
• Grisolano, J. L., Wesselschmidt, R. L., Pelicci, P. G. & Ley, T. J. Altered myeloid development and acute leukemia in transgenic mice expressing PML–RAR α under control of cathepsin G regulatory sequences. Blood 89, 376–387 (1997).
  CAS PubMed Google Scholar
• Trecca, D. et al. Analysis of p53 gene mutations in acute myeloid leukemia. Am. J. Hematol. 46, 304–309 (1994).
  CAS PubMed Google Scholar
• Insinga, A., Pelicci, P. G. & Minucci, S. Leukemia-associated fusion proteins. Multiple mechanisms of action to drive cell transformation. Cell Cycle 4, 67–69 (2005).
  CAS PubMed Google Scholar
• Insinga, A. et al. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J. 23, 1144–1154 (2004). Demonstrates that deacetylation of non-histone substrates (p53) by HDACs has a role in tumorigenesis.
  CAS PubMed PubMed Central Google Scholar
• Bereshchenko, O. R., Gu, W. & Dalla-Favera, R. Acetylation inactivates the transcriptional repressor BCL6. Nature Genet. 32, 606–613 (2002).
  CAS PubMed Google Scholar
• Eckner, R., Arany, Z., Ewen, M., Sellers, W. & Livingston, D. M. The adenovirus E1A-associated 300-kD protein exhibits properties of a transcriptional coactivator and belongs to an evolutionarily conserved family. Cold Spring Harb. Symp. Quant. Biol. 59, 85–95 (1994).
  CAS PubMed Google Scholar
• Iyer, N. G., Ozdag, H. & Caldas, C. p300/CBP and cancer. Oncogene 23, 4225–4231 (2004).
  CAS PubMed Google Scholar
• Kumar, R., Wang, R. A. & Bagheri-Yarmand, R. Emerging roles of MTA family members in human cancers. Semin. Oncol. 30, 30–37 (2003).
  CAS PubMed Google Scholar
• Bagheri-Yarmand, R., Talukder, A. H., Wang, R. A., Vadlamudi, R. K. & Kumar, R. Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development 131, 3469–3479 (2004).
  CAS PubMed Google Scholar
• Zhu, P. et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5, 455–463 (2004).
  CAS PubMed Google Scholar
• Toh, Y. et al. Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int. J. Cancer 110, 362–367 (2004).
  CAS PubMed Google Scholar
• Fraga, M. F. et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genet. 37, 391–400 (2005). References 62 and 63 demonstrate that global histone modifications occur in cancer.
  CAS PubMed Google Scholar
• Seligson, D. B. et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435, 1262–1266 (2005). A coordinated pattern of histone modifications predicts clinical outcome in prostate cancer.
  CAS PubMed Google Scholar
• Egger, G., Liang, G., Aparicio, A. & Jones, P. A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457–463 (2004).
  CAS PubMed Google Scholar
• Feinberg, A. P. & Tycko, B. The history of cancer epigenetics. Nature Rev. Cancer 4, 143–153 (2004).
  CAS Google Scholar
• Lund, A. H. & van Lohuizen, M. Epigenetics and cancer. Genes Dev. 18, 2315–2335 (2004).
  CAS PubMed Google Scholar
• Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Rev. Drug Discov. 1, 287–299 (2002).
  CAS Google Scholar
• Marks, P. et al. Histone deacetylases and cancer: causes and therapies. Nature Rev. Cancer 1, 194–202 (2001).
  CAS Google Scholar
• Mai, A. et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med. Res. Rev. 25, 261–309 (2005).
  CAS PubMed Google Scholar
• Miller, T. A., Witter, D. J. & Belvedere, S. Histone deacetylase inhibitors. J. Med. Chem. 46, 5097–5116 (2003).
  CAS PubMed Google Scholar
• Park, J. H. et al. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin. Cancer Res. 10, 5271–5281 (2004).
  CAS PubMed Google Scholar
• Mai, A. et al. Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. J. Med. Chem. 46, 4826–4829 (2003).
  CAS PubMed Google Scholar
• Heltweg, B. et al. Subtype selective substrates for histone deacetylases. J. Med. Chem. 47, 5235–5243 (2004).
  CAS PubMed Google Scholar
• Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M. & Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl Acad. Sci. USA 100, 4389–4394 (2003).
  CAS PubMed Google Scholar
• Finnin, M. S. et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401, 188–193 (1999).
  CAS PubMed Google Scholar
• Richon, V. M. et al. Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivo. Methods Enzymol. 376, 199–205 (2004).
  CAS PubMed Google Scholar
• Somoza, J. R. et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure (Camb) 12, 1325–1334 (2004).
  CAS Google Scholar
• Vannini, A. et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl Acad. Sci. USA 101, 15064–15069 (2004). References 78 and 79 show the structural analysis of mammalian HDAC8 in complex with HDACi.
  CAS PubMed Google Scholar
• Siddiqui, H., Solomon, D. A., Gunawardena, R. W., Wang, Y. & Knudsen, E. S. Histone deacetylation of RB-responsive promoters: requisite for specific gene repression but dispensable for cell cycle inhibition. Mol. Cell. Biol. 23, 7719–7731 (2003).
  CAS PubMed PubMed Central Google Scholar
• Glaser, K. B. et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2, 151–163 (2003).
  CAS PubMed Google Scholar
• Mitsiades, C. S. et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl Acad. Sci. USA 101, 540–545 (2004).
  CAS PubMed Google Scholar
• Peart, M. J. et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102, 3697–3702 (2005).
  CAS PubMed Google Scholar
• Van Lint, C., Emiliani, S. & Verdin, E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 5, 245–253 (1996). References 81–84 detail gene-profiling studies of the cell transcriptional response to HDACi in different model systems. The results are not always fully consistent among the different systems (the number of modulated genes varies from <5% to 20%).
  CAS PubMed Google Scholar
• Camphausen, K. et al. Enhanced radiation-induced cell killing and prolongation of gH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res. 64, 316–321 (2004).
  CAS PubMed Google Scholar
• Munshi, A. et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin. Cancer Res. 11, 4912–4922 (2005).
  CAS PubMed Google Scholar
• Warrener, R. et al. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J. 17, 1550–1552 (2003).
  CAS PubMed Google Scholar
• Beamish, H., Warrener, R. & Gabrielli, B. G. Analysis of checkpoint responses to histone deacetylase inhibitors. Methods Mol. Biol. 281, 245–259 (2004).
  CAS PubMed Google Scholar
• Qiu, L. et al. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol. Biol. Cell 11, 2069–2083 (2000).
  CAS PubMed PubMed Central Google Scholar
• Richon, V. M., Sandhoff, T. W., Rifkind, R. A. & Marks, P. A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl Acad. Sci. USA 97, 10014–10019 (2000).
  CAS PubMed Google Scholar
• Gui, C. Y., Ngo, L., Xu, W. S, Richon, V. M. & Marks, P. A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl Acad. Sci. USA 101, 1241–1246 (2004).
  CAS PubMed Google Scholar
• Varshochi, R. et al. ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor α from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line. J. Biol. Chem. 280, 3185–3196 (2005).
  CAS PubMed Google Scholar
• Archer, S. Y., Meng, S., Shei, A. & Hodin, R. A. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl Acad. Sci. USA 95, 6791–6796 (1998).
  CAS PubMed Google Scholar
• Shao, Y., Gao, Z., Marks, P. A. & Jiang, X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 101, 18030–18035 (2004).
  CAS PubMed Google Scholar
• Rosato, R. R., Almenara, J. A., Grant, S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 63, 3637–3645 (2005).
  Google Scholar
• Ungerstedt, J. S. et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102, 673–678 (2005).
  CAS PubMed Google Scholar
• Subramanian, C., Opipari, A. W., Bian, X., Castle, V. P. & Kwok, R. P. Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102, 4842–4847 (2005).
  CAS PubMed Google Scholar
• Atadja, P. et al. Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. Novartis Found. Symp. 259, 249–266 (2004).
  CAS PubMed Google Scholar
• Bali, P. et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280, 26729–26734 (2005).
  CAS PubMed Google Scholar
• Hideshima, T. et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl Acad. Sci. USA 102, 8567–8572 (2005).
  CAS PubMed Google Scholar
• Insinga, A. et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nature Med. 11, 71–76 (2005).
  CAS PubMed Google Scholar
• Nebbioso, A. et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Med. 11, 77–84 (2005). References 101 and 102 demonstrate the essential role of induction of the TRAIL pathway for the pro-apoptotic response following HDACi treatment in leukaemias.
  CAS PubMed Google Scholar
• Inoue, H. et al. Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis. Int. J. Mol. Med. 9, 521–525 (2002).
  CAS PubMed Google Scholar
• Nakata, S. et al. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23, 6261–6271 (2004).
  CAS PubMed Google Scholar
• Singh, T. R., Shankar, S. & Srivastava, R. K. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 24, 4609–4623 (2005).
  CAS PubMed Google Scholar
• Watanabe, K., Okamoto, K. & Yonehara, S. Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ. 12, 10–18 (2005).
  CAS PubMed Google Scholar
• Rosato, R. R. & Grant, S. Histone deacetylase inhibitors in clinical development. Expert Opin. Investig. Drugs 13, 21–38 (2004).
  CAS PubMed Google Scholar
• Johnstone, R. W. & Licht, J. D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4, 13–18 (2003).
  CAS PubMed Google Scholar
• Drummond, D. C. et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 45, 495–528 (2004).
  Google Scholar
• Chavez-Blanco, A. et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol. Cancer 4, 22 (2005).
  PubMed PubMed Central Google Scholar
• Kelly, W. K. et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23, 3923–3931 (2005).
  CAS PubMed PubMed Central Google Scholar
• Kelly, W. K. et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9, 3578–3588 (2003).
  CAS PubMed Google Scholar
• Ryan, Q. C. et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 23, 3912–3922 (2005).
  CAS PubMed Google Scholar
• Piekarz, R. L. et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98, 2865–2868 (2001).
  CAS PubMed Google Scholar
• Sandor, V. et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8, 718–728 (2002).
  CAS PubMed Google Scholar
• Piekarz, R. L. et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103, 4636–4643 (2004).
  CAS PubMed Google Scholar
• Bandyopadhyay, D., Mishra, A. & Medrano, E. E. Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res. 64, 7706–7710 (2004).
  CAS PubMed Google Scholar
• Xiao, J. J. et al. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J. Pharmacol. Exp. Ther. 314, 467–475 (2005).
  CAS PubMed Google Scholar
• Pilatrino, C. et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 104, 101–109 (2005).
  CAS PubMed Google Scholar
• Cameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G. & Baylin, S. B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21, 103–107 (1999).
  CAS PubMed Google Scholar
• Rahmani, M. et al. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr–Abl+ cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr–Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol. Pharmacol. 67, 1166–1176 (2005).
  CAS PubMed Google Scholar
• Girdwood, D. W., Tatham, M. H. & Hay, R. T. SUMO and transcriptional regulation. Semin. Cell Dev. Biol. 15, 201–210 (2004).
  CAS PubMed Google Scholar
• Al-Hajj, M., Becker, M. W., Wicha, M., Weissman, I. & Clarke, M. F. Therapeutic implications of cancer stem cells. Curr. Opin. Genet. Dev. 14, 43–47 (2004).
  CAS PubMed Google Scholar
• Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105–111 (2001).
  CAS PubMed Google Scholar
• Milhem, M. et al. Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A. Blood 103, 4102–4110 (2004). An initial study on the effects of HDACi on stem cells.
  CAS PubMed Google Scholar
• Guenther, M. G. et al. A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev. 14, 1048–1057 (2000).
  CAS PubMed PubMed Central Google Scholar
• Huang, E. Y. et al. Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes Dev. 14, 45–54 (2000).
  CAS PubMed PubMed Central Google Scholar
• Humphrey, G. W. et al. Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1. J. Biol. Chem. 276, 6817–6824 (2001).
  CAS PubMed Google Scholar
• Jones, P. L., Sachs, L. M., Rouse, N., Wade, P. A. & Shi, Y. B. Multiple N-CoR complexes contain distinct histone deacetylases. J. Biol. Chem. 276, 8807–8811 (2001).
  CAS PubMed Google Scholar
• Li, J. et al. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J. 19, 4342–4350 (2000).
  CAS PubMed PubMed Central Google Scholar
• Xue, Y. et al. NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Mol. Cell 2, 851–861 (1998).
  CAS PubMed Google Scholar
• Yao, Y. L. & Yang, W. M. The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity. J. Biol. Chem. 278, 42560–42568 (2003).
  CAS PubMed Google Scholar
• Zhang, Y. et al. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 13, 1924–1935 (1999).
  CAS PubMed PubMed Central Google Scholar
• Seigneurin-Berny, D. et al. Identification of components of the murine histone deacetylase 6 complex: link between acetylation and ubiquitination signaling pathways. Mol. Cell. Biol. 21, 8035–8044 (2001).
  CAS PubMed PubMed Central Google Scholar
• Yamagoe, S. et al. Interaction of histone acetylases and deacetylases in vivo. Mol. Cell. Biol. 23, 1025–1033 (2003).
  CAS PubMed PubMed Central Google Scholar
• Fischle, W. et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 9, 45–57 (2002).
  CAS PubMed Google Scholar
• Verdin, E., Dequiedt, F. & Kasler, H. G. Class II histone deacetylases: versatile regulators. Trends Genet. 19, 286–293 (2003).
  CAS PubMed Google Scholar
• Gore, S. D. et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 8, 963–970 (2002).
  CAS PubMed Google Scholar
• Patnaik, A. et al. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin. Cancer Res. 8, 2142–2148 (2002).
  CAS PubMed Google Scholar
• Raffoux, E., Chaibi, P., Dombret, H. & Degos, L. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 90, 986–988 (2005).
  CAS PubMed Google Scholar
• Byrd, J. C. et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105, 959–967 (2005).
  CAS PubMed Google Scholar